Company profile
Evgen Pharma | Sulforaphane-Based Clinical Drug Development
Evgen Pharma is a clinical drug development company developing sulforaphane-based medicines focussed on the treatment of cancer and inflammation.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last confirmation statement made up date
Last accounts made up date
CS01 | Transaction MzQ0MTU5NzM3MGFkaXF6a2N4
Published 31 Oct 2024 11:46
PSC05 | Transaction MzQzOTE0Nzc4MWFkaXF6a2N4
Published 11 Oct 2024 09:06
Company registered at Companies House
1 Jul 2012 to 31 May 2013
Sulforaphane, a small molecule of botanical origin, has previously shown significant clinical promise for treating some forms of cancer. However, it is highly unstable rendering it - until now - a nonviable pharmaceutical. In a significant technical breakthrough, Evgen is now able to stabilise a synthetic sulforaphane - extending shelf life from hours to ...
